Skip to main content
. 2019 Nov 26;11(12):1095. doi: 10.3390/v11121095

Figure 1.

Figure 1

PFV-mediated ISG induction in myeloid cells. (a,b) Kinetics of ISG56/ISG54 induction in PMA-differentiated THP-1 wild type cells incubated with different amounts of wild type PFV-RCP (a, MOI 0.2) as well as pUC19 (mock A) mock supernatants. ISG mRNA levels normalized for RPL13A mRNA levels were determined by qPCR at the indicated time points post exposure. Means ± SDs of ISG56 (n = 4; a) or ISG54 (n = 4; b) induction relative to mock A treatment are shown. (c,d) Primary human MDDC (c) or MDM (d) were incubated with wild type PFV-RCP (PFV; MOI 0.25), ∆GPE (mock B) mock supernatant, or medium (medium) for 6, 12, or 24 h, as indicated. Means ± SEMs, plus individual data points, of ISG54 (n = 5–8) induction normalized to RPL13A relative to medium treatment are shown. Mixed-effects analysis with Holm–Sidak’s multiple-comparisons test was used to assess significance. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; ns: not significant (p ≥ 0.05).